Our Impact

ICRF is proud of the many awardees that have been and continue to be involved in major cancer research breakthroughs. Selected achievements made possible by ICRF funding include:

Velcade® – a drug used to treat multiple myeloma, a cancer of the bone marrow, was developed based on the research of ICRF Research Professorship Grant Recipients and Nobel Laureates Drs. Avram Hershko and Aaron Ciechanover of the Technion, Israel Institute of Technology.


Gleevec® – the first drug to directly target cancer cells was developed based on the research work of ICRF grantee Dr. Eli Canaani of the Weizmann Institute of Science.


Doxil® – the first drug encapsulated in a liposome (or microscopic fat bubble) for direct delivery to a tumor site was developed by ICRF awardee Dr. Alberto Gabizon of the Shaare Zedek Medical Center.


The p53 Gene – Originally thought to cause cancer, was correctly identified as a tumor suppressor, and its role in the majority of human cancers further elucidated by ICRF awardees Drs. Moshe Oren and Varda Rotter of the Weizmann Institute of Science.


DNA Methylation – is a molecular process that turns genes on and off. Pioneering work in this area was performed by ICRF Research Professorship Grantee and Israel Prize winner, Dr. Howard Cedar of the Hebrew University-Hadassah Medical School.


The RAD51 Gene – The discovery that a minor mutation in this gene increases the risk of breast cancer in women with the BRCA2 gene mutation was made by ICRF awardee Dr. Ephrat Levy-Lahad of the Shaare Zedek Medical Center.


A Novel Bone Marrow Transplant Technique – to greatly expand the donor pool for leukemia treatment was developed by ICRF awardee Dr. Yair Reisner of the Weizmann Institute of Science.